Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2019 · 10-Q
Revenue$7.73M$7.73M+34.3% vs Q3 2018 Net Income-$7.45M-$7.45MN/M vs Q3 2018 EPS Diluted-$1.97-$1.97N/M vs Q3 2018 Gross Profit$2,890,000−3.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,771,000N/M Free Cash Flowderived-$4,828,000N/M Margins · derivedGross margin37.4%−14.6 pt vs Q3 2018
Operating margin-92.3%−49.5 pt vs Q3 2018
Net margin-96.4%−42.1 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end